

Page 10, after the second sequence insert -- SEQ ID NO: 2 --.

Page 10, after the third sequence insert -- SEQ ID NO: 3 --.

Page 10, after the fourth sequence insert -- SEQ ID NO: 4 --.

Page 11, after the first sequence insert -- SEQ ID NO: 5 --.

Page 11, after the second sequence insert -- SEQ ID NO: 6 --.

Page 22, after the first sequence insert -- SEQ ID NO: 7 --.

Page 22, after the second sequence insert -- SEQ ID NO: 8 --.

Page 23, after the first sequence insert -- SEQ ID NO: 9 --.

Page 23, after the second sequence insert -- SEQ ID NO: 10 --.

Page 27, after the first sequence insert -- SEQ ID NO: 11 --.

Page 27, after the second sequence insert -- SEQ ID NO: 12 --.

Page 27, after the third sequence insert -- SEQ ID NO: 13 --.

Page 27, after the fourth sequence insert -- SEQ ID NO: 14 --.

Page 27, after the fifth sequence insert -- SEQ ID NO: 15 --.

Page 27, after the sixth sequence insert -- SEQ ID NO: 16 --.

Page 27, after the seventh sequence insert -- SEQ ID NO: 17 --.

Page 27, after the eighth sequence insert -- SEQ ID NO: 18 --.

Page 27, after the ninth sequence insert -- SEQ ID NO: 19 --

Page 27, after the tenth sequence insert -- SEQ ID NO: 20 --

Page 27, after the eleventh sequence insert -- SEQ ID NO: 21 --

Page 27, after the twelfth sequence insert -- SEQ ID NO: 22 --

Page 27, after the thirteenth sequence insert -- SEQ ID NO: 23 --

Page 27, after the fourteenth sequence insert -- SEQ ID NO: 24 --

Page 27, after the fifteenth sequence insert -- SEQ ID NO: 25 --

Page 27, after the sixteenth sequence insert -- SEQ ID NO: 26 --

**In the Claims:**

Cancel claims 13, 23, 27, 29 and 31-34.

Amend claims 9, 12, 14, 17-19, 22, 24, 28 and 30 by adding the underlined language and deleting the bracketed language as follows:

*Sub C*  
*B*

9. (Amended once) [An] A polypeptide analog of the Bordetella exotoxin S1 subunit, said analog [having] differing in amino acid sequence from that of the naturally occurring S1 subunit by the substitution of one or more amino acid residues in the region bounded by valine 7 and proline 14, inclusively, wherein the analog has a biological activity which (a) can elicit toxin-neutralizing levels of antibodies and (b) is free of enzymatic activities associated with [toxin] exotoxin reactogenicity.